Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study on the Effectiveness and Safety of a Vaccine with Dendritic Cells for Patients with Newly Diagnosed Glioblastoma

Verified siteInvestigational
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying a type of brain cancer called glioblastoma, which is a newly diagnosed and aggressive form of cancer. The treatment being tested is a vaccine made from the patient's own immune cells, specifically autologous, tumor lysate-loaded, mature dendritic cells. This vaccine, known by the code name GlioVax, is given as an injection. The purpose of the study is to see if adding this vaccine to the standard treatment can help patients live longer compared to receiving the standard treatment alone.

The standard treatment for glioblastoma includes surgery to remove as much of the tumor as possible, followed by radiotherapy and chemotherapy with a drug called temozolomide. In this study, patients will receive the GlioVax vaccine in addition to these standard treatments. The vaccine is given intradermally, which means it is injected into the skin. The study will monitor patients over a period of time to assess their overall survival and any potential side effects from the vaccine.

Participants in the study will be closely observed to determine how well they respond to the treatment and to ensure their safety. The study will also evaluate the quality of life and neurological performance of the patients using various assessments. The goal is to find out if the vaccine can improve outcomes for patients with glioblastoma when used alongside the usual care. The study is expected to continue until 2027, providing valuable insights into the potential benefits of this new treatment approach.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial treatment and surgery

    The trial begins with the diagnosis of newly diagnosed glioblastoma. The patient undergoes a surgical procedure to remove the tumor. The goal is to achieve a near-complete resection, leaving a residual tumor volume of 5 ml or less.

    A sterile tumor sample of at least 150 mg is collected during surgery. This sample is used to produce the personalized vaccine.

  2. Step 2

    Vaccine preparation

    The collected tumor sample is processed to create a vaccine. This vaccine consists of autologous mature dendritic cells loaded with the patient's own tumor lysate. The term 'autologous' means that the cells are derived from the patient's own body.

  3. Step 3

    Standard radiochemotherapy

    Following surgery, the patient receives standard treatment, which includes radiotherapy combined with temozolomide chemotherapy. Temozolomide is a medication taken orally to help fight cancer cells.

  4. Step 4

    Vaccine administration

    The personalized vaccine is administered through an intradermal injection. This means the vaccine is injected into the skin. The schedule and frequency of these injections are determined by the study protocol.

  5. Step 5

    Adjuvant chemotherapy

    After completing the initial radiochemotherapy, the patient continues with adjuvant temozolomide chemotherapy. This phase involves additional cycles of temozolomide to further target cancer cells.

  6. Step 6

    Monitoring and follow-up

    Throughout the trial, the patient's health and response to treatment are closely monitored. This includes regular MRI scans to check for tumor progression and assessments of overall and neurological performance.

    The patient's quality of life is evaluated using specific questionnaires designed to measure well-being and psychological stress.

Who can join the trial?

10 criteria

  • The patient must have a newly diagnosed condition called glioblastoma, which is a type of brain tumor.
  • The tumor must be monofocal, meaning it is located in one area, and it should be IDH wildtype, a specific genetic type of glioblastoma.
  • The tumor should be classified as WHO grade IV, which is a way to describe the severity of the tumor.
  • The tumor can include certain types called gliosarcoma and giant cell glioblastoma.
  • The tumor may extend into, but not beyond, a part of the brain called the corpus callosum.
  • A near-complete resection of the tumor must have been performed, meaning most of the tumor has been surgically removed, with no more than 5 milliliters of the tumor left, as confirmed by an MRI scan within 72 hours after surgery.
  • The surgery can be done while the patient is awake, and a second surgery is possible if needed for medical reasons.
  • A sterile tumor sample of at least 150 milligrams must be available, with at least 60% of the sample containing tumor cells, for the purpose of making a vaccine.
  • Both male and female patients can participate in the study.
  • The study includes patients who may be considered part of a vulnerable population, which means they might need extra protection or care.

Who cannot join the trial?

6 criteria

  • Patients who have not been newly diagnosed with glioblastoma, which is a type of brain cancer.
  • Patients who are not within the specified age range for the study.
  • Patients who do not belong to the specific clinical trial group required for the study.
  • Patients who are not able to receive the standard treatment, which includes surgery, radiation therapy, and chemotherapy with a drug called temozolomide.
  • Patients who are unable to receive the additional treatment being tested in the study, which involves a special type of vaccine.
  • Patients who are part of a vulnerable population that the study is not designed to include.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Temozolomide

    is a chemotherapy medication used in the treatment of glioblastoma, a type of brain cancer. It works by damaging the DNA of cancer cells, which prevents them from dividing and growing. In this trial, temozolomide is used alongside radiotherapy as part of the standard treatment for newly diagnosed glioblastoma patients.

  • Lysate-loaded, mature dendritic cell vaccines

    are a type of immunotherapy used in this trial. These vaccines are made by loading dendritic cells, which are a type of immune cell, with tumor lysates. The goal is to stimulate the patient's immune system to recognize and attack glioblastoma cells more effectively. This therapy is being tested as an additional treatment to the standard care for glioblastoma.

What is already known about the treatment

Dendritic Cell Vaccine – This medication is administered as an injection, typically given under the skin. It is currently being studied in clinical trials for its potential use in treating newly diagnosed glioblastoma, a type of brain cancer. The main therapeutic indication is to improve overall survival in patients when used alongside standard treatments like surgery, radiation, and chemotherapy. At the molecular level, the vaccine works by stimulating the immune system to recognize and attack cancer cells. It is classified as an immunotherapy, which is a type of treatment that uses the body's own immune system to fight cancer.

Investigated diseases

Glioblastoma – Glioblastoma is a type of brain cancer that originates from glial cells, which support nerve cells in the brain. It is known for its aggressive nature and rapid growth, often infiltrating surrounding brain tissue. Symptoms can include headaches, seizures, and neurological deficits such as weakness or speech difficulties, depending on the tumor's location. The disease typically progresses quickly, with tumor cells spreading into nearby brain areas, making complete surgical removal challenging. As the tumor grows, it can cause increased pressure within the skull, leading to further neurological symptoms. The progression of glioblastoma is often monitored through imaging techniques like MRI to assess changes in tumor size and spread.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IITrial ID2024-514820-18-00Protocol codeGlioVaxEstimated enrolment136 patientsSponsorHeinrich-Heine-Universitaet Duesseldorf

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).